<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2
Under the Securities Exchange Act of 1934
TRANSKARYOTIC THERAPIES, INC.
-----------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $.01 PER SHARE
--------------------------------------
(Title of Class of Securities)
893735-10-0
-----------
(CUSIP Number)
Check the following box if a fee is being paid with the statement [ ].
(A fee is not required only if the reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five percent of
the class of securities described in Item 1; and (2) has filed no amendment
subsequent thereto reporting beneficial ownership of five percent or less of
such class.) (See Rule 13d-7.)
Page 1 of 10 Pages
<PAGE> 2
CUSIP No. 893735-10-0 13G
- ---------------------
- ----------------------------------------------------------------------
(1) Name of Reporting Persons
S.S. or I.R.S. Identification No. of Above Persons
BB Biotech AG
- ----------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) [ ]
of a Group* (b) [x]
- ----------------------------------------------------------------------
(3) SEC Use Only
- ----------------------------------------------------------------------
(4) Citizenship or Place of Organization
Swiss
- ----------------------------------------------------------------------
Number of Shares (5) Sole Voting Power
Beneficially Owned 0
by Each Reporting -------------------
Person With (6) Shared Voting Power
1,300,000
----------------------
(7) Sole Dispositive Power
0
-------------------
(8) Shared Dispositive Power
1,300,000
-------------------
- ----------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
1,300,000
- ----------------------------------------------------------------------
(10) Check Box if the Aggregate Amount in Row (9)
Excludes Certain Shares* [ ]
- ----------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
7.83
- ----------------------------------------------------------------------
(12) Type of Reporting Person*
HC, CO
- ----------------------------------------------------------------------
Page 2 of 10 Pages
<PAGE> 3
CUSIP No. 893735-10-0 13G
- ---------------------
- ----------------------------------------------------------------------
(1) Name of Reporting Persons
S.S. or I.R.S. Identification No. of Above Persons
Biotech Target, S.A.
- ----------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) [ ]
of a Group* (b) [x]
- ----------------------------------------------------------------------
(3) SEC Use Only
- ----------------------------------------------------------------------
(4) Citizenship or Place of Organization
Panama
- ----------------------------------------------------------------------
Number of Shares (5) Sole Voting Power
Beneficially Owned 0
by Each Reporting -------------------
Person With (6) Shared Voting Power
1,300,000
---------------------
(7) Sole Dispositive Power
0
-------------------
(8) Shared Dispositive Power
1,300,000
-------------------
- ----------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
1,300,000
- ----------------------------------------------------------------------
(10) Check Box if the Aggregate Amount in Row (9)
Excludes Certain Shares* [ ]
- ----------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
7.83
- ----------------------------------------------------------------------
(12) Type of Reporting Person*
CO
- ----------------------------------------------------------------------
Page 3 of 10 Pages
<PAGE> 4
Securities and Exchange Commission
Washington, D.C.
Schedule 13G
ITEM 1(a). NAME OF ISSUER:
Transkaryotic Therapies, Inc.
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
195 Albany Street, Cambridge, MA 02139
ITEM 2(a). NAME OF PERSON FILING:
Biotech Target, S.A. ("Biotech Target")
BB Biotech AG ("BB Biotech")
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Biotech Target's business address is Swiss Bank
Tower, Panama 1, Republic of Panama.
BB Biotech AG's business address is Vordergasse 3,
8200 Schaffhausen, CH/Switzerland.
ITEM 2(c). CITIZENSHIP:
BB Biotech: Swiss
Biotech Target: Panamanian
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock, (par value $.01 per share)
Page 4 of 10 Pages
<PAGE> 5
ITEM 2(e). CUSIP NUMBER:
893735-10-0
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b), OR
13d-2(b), CHECK WHETHER THE PERSON FILING IS A:
Not Applicable
ITEM 4. OWNERSHIP.
(a) Amount beneficially owned: 1,300,000
(b) Percent of class: 7.83%
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 1,300,000
(iii) Sole power to dispose or to direct the disposition of: 0
(iv) Shared power to dispose or to direct the disposition of:
1,300,000
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not Applicable
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
PERSON.
Not Applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY.
Not Applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
See Exhibit I which is incorporated herein by
reference.
Page 5 of 10 Pages
<PAGE> 6
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not Applicable.
ITEM 10. CERTIFICATION.
Not Applicable. Statement is being filed pursuant to
Rule 13d-1(c).
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
BB BIOTECH AG
Date: February 21, 1997 By:/s/ Hans-Joerg Graf*
--------------------
Name: Hans-Joerg Graf
By:/s/ Dr. Victor Bischoff*
------------------------
Name: Dr. Victor Bischoff
BIOTECH TARGET, S.A.
Date: February 21, 1997 By:/s/ Dr. Andreas Bremer
----------------------
Name: Dr. Andreas Bremer
By:/s/ Daniel Bugman
-----------------
Name: Daniel Bugman
- ----------------
* See power of attorney, attached as an exhibit 99.E to BB Biotech's Schedule
13D relating to Biogen, Inc. filed with the Securities and Exchange Commission
on June 2, 1994.
Page 6 of 10 Pages
<PAGE> 7
EXHIBIT INDEX
Exhibit I Identification and Classification of Members of the Group
Exhibit II Statement of BB Biotech AG
Exhibit III Statement of Biotech Target, S.A.
Page 7 of 10 Pages
<PAGE> 8
EXHIBIT I
This statement is being filed jointly by BB Biotech AG, a
Swiss corporation ("BB Biotech") and Biotech Target S.A., a Panamanian
corporation ("Biotech Target"). Biotech Target is a wholly owned subsidiary of
BB Biotech.
Page 8 of 10 Pages
<PAGE> 9
EXHIBIT II
BB Biotech AG ("BB Biotech") disclaims beneficial ownership of the
securities referred to in the Schedule 13G to which this exhibit is attached,
and the filing of this Schedule 13G shall not be construed as an admission that
BB Biotech is, for the purpose of Section 13(d) or 13(g) of the Securities
Exchange Act of 1934, the beneficial owner of any securities covered by this
Schedule 13G.
Pursuant to Rule 13d-1(f)(1) and subject to the preceding disclaimer,
BB Biotech affirms that it is individually eligible to use Schedule 13G and
agrees that this Schedule 13G is filed on its behalf.
BB BIOTECH AG
Date: February 21, 1997 By:/s/ Hans-Joerg Graf
-------------------
Name: Hans-Joerg Graf
By:/s/ Dr. Victor Bischoff
-----------------------
Name: Dr. Victor Bischoff
Page 9 of 10 Pages
<PAGE> 10
EXHIBIT III
Pursuant to Rule 13d-1(f)(1), Biotech Target, S.A. affirms that it is
individually eligible to use Schedule 13G and agrees that this Schedule 13G is
filed on its behalf.
BIOTECH TARGET, S.A.
Date: February 21, 1997 By:/s/ Dr. Andreas Bremer
----------------------
Name: Dr. Andreas Bremer
By:/s/ Daniel Bugman
-----------------
Name: Daniel Bugman
Page 10 of 10 Pages
